SOMERVILLE, Mass., November 14, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...

Inc. ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company to solicit ...

bluebird bio, Inc. (NASDAQ: BLUE ... in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) yesterday and set a price ...

bluebird bio’s board of directors strongly encourages that stockholders ... developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive ...

bluebird bio is to ask regulators to restart clinical ... evidence demonstrating that it is very unlikely our BB305 lentiviral vector played a role in this case and we have shared with the FDA ...

Europe's market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided ... as a result of the lentiviral vector used ...

It was untreatable until the FDA in 2022 granted Bluebird Bio’s gene therapy Skysona (elivaldogene autotemcel ... Skysona involves placing a healthy form of the gene onto a lentivirus vector that is ...

SOMERVILLE, Mass., November 06, 2024--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of ...